scholarly journals Correlation of hormone receptors with her 2/neu protein expression and the histological grade in invasive breast cancers in a cohort of saudi arabia

2010 ◽  
Vol 26 (3) ◽  
pp. 209 ◽  
Author(s):  
Maha Arafah
Keyword(s):  
Saudi Arabia ◽  
Protein Expression ◽  
Hormone Receptors ◽  
Histological Grade ◽  
Breast Cancers ◽  
Her 2

scholarly journals HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors

2007 ◽  
Vol 15 (1-2) ◽  
pp. 15-18 ◽  
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Slavica Knezevic-Usaj ◽  
Milana Panjkovic ◽  
Dragana Ðilas-Ivanovic ◽  
Mileta Golubovic
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Histological Grade ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Protein Overexpression ◽  
Large Tumor ◽  
Invasive Ductal Breast Cancer ◽  
Ductal Breast Cancer ◽  
Her 2

Background: HER-2/neu is a proto-oncogene that is amplified/overexpressed in 15 to 30% of invasive breast cancers. The purpose of this study was to determine if any relationship exist between HER-2/neu protein overexpression and estrogen receptor (ER), progesterone receptor (PR), grade, size, and lymph node status in female breast cancer. Methods: A total of 100 cases of invasive ductal breast cancer were included in this study. The hormone receptors and HER-2/neu were studied immunohistochemically (IHC). Using the HER-2/neu DAKO scoring system, scores of 0, 1+ and 2+ were defined as negative and 3+ as positive. Results: HER-2/neu protein overexpression was seen in 20 (20%) of cases. HER-2/neu protein overexpression was present in 4 of 52 T1 lesions (8%), in 11 of 37 T2 lesions (30%), in 3 of 6 T3 lesions (50%), and in 2 of 5 T4 lesions (40%), (p<0.05). Protein overexpression was seen in 7 of 17 grade III tumors (41%), and 13 of 61 grade II tumors (21%). Overexpression was not detected in grade I tumors (p<0.01). Of the 20 Her-2/neu positive cases, ER- and PR-negative status was detected in 60% and 70%, respectively. Conclusion: Statistically significant correlation was found between HER-2/neu protein overexpression and large tumor size, high histological grade, and ER-, PR-negativity. There was no correlation with lymphonodal status.

Evaluation of HER-2 expression in breast cancer using image analysis incorporating automatic feature recognition

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20007-20007
Author(s):  
C. Murray ◽  
J. Maddison ◽  
C. Anderson ◽  
D. Challender ◽  
S. Palmer ◽  
...  
Keyword(s):  
Image Analysis ◽  
Protein Expression ◽  
Feature Recognition ◽  
Dynamic Range ◽  
In Situ Hybridisation ◽  
Automated Image Analysis ◽  
City Hospital ◽  
Breast Cancers ◽  
Automatic Feature Recognition ◽  
Her 2

20007 The currently favoured method for evaluation of HER-2 in routine clinical practice and research studies is immunohistochemistry (IHC). As standardised scoring of protein expression, using a scale of 0 - 3+, generates a significant number of false positives, fluorescent in situ hybridisation (FISH) is used to confirm the presence of gene amplification. Both techniques are laborious, and in the case of by-eye scoring of IHC, semi-quantitative at best. We have developed a high-throughput platform for the quantitative analysis of immunostained slides, based on fast, high-resolution scanning followed by analysis of digitised images (IA) using proprietary software, and in this study compared results obtained using this platform with those obtained using conventional methods. Archival sections of primary breast cancers collected at Nottingham City Hospital in 2004 and 2005 were stained for HER-2 (Herceptest, Dako), and evaluated by eye. Equal numbers of slides from scoring categories 0–3+ were then selected for further image analysis. The digitised images were subjected to automatic delineation to define areas of tumour parenchyma, and these areas further analysed using colour segmentation. Between 100 and 2000 fields were quantified on each section. Staining was expressed as a product of field fraction of coloured pixels and optical density. The results of IA demonstrate a continuum of staining values over the four conventional by-eye categories, with a non-linear correlation to by-eye scores. Inter-sample variation was greatest in the 3+ category, although the mean was much higher than that of the 2+ samples. The 2+ samples showed some variation, with several values not rising above baseline. To further investigate the relationship between FISH scores and IA results in the 2+ category, we analysed an additional set of slides in this group, and found a correlation between FISH and automated IA scores. We conclude that automated image analysis is sensitive to small differences in protein expression, has a wide dynamic range, and provides data superior to conventional by-eye scoring. In undecided cases HER-2 protein expression correlates with FISH data; therefore ultimately IA of HER-2 protein expression alone may provide a basis for clinical decisions. [Table: see text]

HER2 assessment and Ki-67 labeling index in a cohort of male breast cases: The Ich Network on Cancer Research (INCaRe) experience.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 623-623
Author(s):  
Giovanna Masci ◽  
Michele Caruso ◽  
Agnese Losurdo ◽  
Piermario Salvini ◽  
Carlo Carnaghi ◽  
...  
Keyword(s):  
Cancer Research ◽  
Hormone Receptors ◽  
Treatment Strategies ◽  
Male Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Ki 67 ◽  
Her 2 ◽  
Female Counterpart

623 Background: The overall incidence of male breast cancers (MBC) is around 1% of all breast cancers and is on the rise.Most of our current knowledge regarding its biology and treatment strategies has been extrapolated from its female counterpart. However, from literature data, it is more and more evident that MBC has biological differences compared with female breast cancer (FBC). While hormone receptors are more frequently positive in MBC than in FBC, HER-2 seems to be less expressed in MBC than in FBC, with data ranging from 0 to 18%; no data on Ki-67 have been so far reported. Methods: We retrospectively analyzed the immunohistochemical expression of hormone receptors status, HER-2 protein expression, and Ki-67 in 76 consecutive MBCs, treated within the Humanitas Institutes Network on Cancer Research (INCaRe). HER-2 determinations were carried out according to ASCO/ACP and NEQAS guidelines: cases with score 2+ at IHC were further examined by fluorescent in situ hybridation (FISH). Results: From 2000 to 2011, we treated 76 male breast cases (age 25-87, median 64): 72 patients (94%) had ductal carcinoma and 4 had rare histotypes (2 papillary, 1 mucinous and 1 cribryform). Thirthy-two of 76 patients (42%) had positive axillary lymph-nodes, while 6 (8%) were metastatic at diagnosis. Of these, estrogen receptor and progesterone receptor were positive in 96% and 93% patients respectively; HER-2, evaluable in 67 patients, was positive in 11 (16%). Ki-67 was evaluable in 75 patients and was > 20% in 24 cases (32%), with 20/24 (26%) with Ki-67 > 30%. Grading was evaluable in 65 patients: G1 in 2 (3%), G2 in 41(63%) and G3 in 22 (34%), respectively. Conclusions: In these series, MBC show different patterns from FBC, with some favorable aspects such as higher hormone receptor status and much lower HER-2 expression and some unfavorable features, such as higher Ki-67 values. Although further studies are needed to confirm these data, different treatment strategies would be suggested in MBC than its female counterpart.

Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System

1999 ◽  
Vol 17 (7) ◽  
pp. 1983-1983 ◽  
Author(s):  
Timothy W. Jacobs ◽  
Allen M. Gown ◽  
Hadi Yaziji ◽  
Melissa J. Barnes ◽  
Stuart J. Schnitt
Keyword(s):  
United States ◽  
Protein Expression ◽  
Drug Administration ◽  
Scoring System ◽  
Food And Drug Administration ◽  
The United States ◽  
Breast Cancers ◽  
United States Food ◽  
Her 2 ◽  
States Food

PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer. MATERIALS AND METHODS: Forty-eight invasive breast cancers previously found to be HER-2/neu–negative by two different immunohistochemical (IHC) assays and not amplified for the HER-2/neu gene by fluorescence in situ hybridization were studied using the HercepTest kit. HercepTest was performed according to the manufacturer's guidelines, and the results were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)–approved grading system. In this system, cases scored as 2+ or 3+ are considered HER-2/neu–positive. RESULTS: Among these 48 cases, the IHC score using the FDA-approved scoring system was 0 in four cases (8.3%), 1+ in 16 (33.3%), 2+ in 21 (43.8%), and 3+ in seven (14.6%). Therefore, 58.4% of these cases were categorized as HER-2/neu–positive, and the specificity of the HercepTest kit for HER-2/neu expression was 41.6%. However, with the use of a modified scoring system that took into account the level of staining of nonneoplastic epithelium, the specificity increased to 93.2%. CONCLUSION: Our results indicate that the HercepTest kit, when used in accordance with the manufacturer's guidelines and the FDA-approved scoring system, results in a large proportion of breast cancers being categorized as positive for HER-2/neu protein expression and that many of these seem to be false-positives. Consideration of the level of staining of nonneoplastic epithelium resulted in improved specificity. The current FDA-approved scoring system for HercepTest results should be reevaluated before its widespread use in clinical practice.

scholarly journals Basal-Like Phenotype in a Breast Carcinoma Case Series from Sudan: Prevalence and Clinical/Pathological Correlations

2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Khalid Dafaallah Awadelkarim ◽  
Carmelo Arizzi ◽  
Elgizouli Omer Musa Elamin ◽  
Hussein M. A. Hamad ◽  
Pasquale De Blasio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Case Series ◽  
Hierarchical Cluster ◽  
Breast Cancers ◽  
Central Sudan ◽  
Younger Age ◽  
Basal Like Breast Cancer ◽  
Her 2 ◽  
Aggressive Subtype

Basal-like breast cancer, an aggressive subtype associated with high grade, poor prognosis, and younger age, is reported frequently in Africa. We analyzed the expression of the basal cytokeratins (CKs) 5/6 and 17 in a case series from Central Sudan and investigated correlations among basal CK status, ER, PgR, and Her-2/neu, and individual/clinicopathological data. Of 113 primary breast cancers 26 (23%), 38 (34%), and 46 (41%) were, respectively, positive for CK5/6, CK17, and combined basal CKs (CK5/6 and/or CK17). Combined basal CK+ status was associated with higher grade (P<.03) and inversely correlated with ER (P<.002), PgR (P=.004) and combined ER and/or PgR (P<.0002). Two clusters based on all tested markers were generated by hierarchical cluster analysis and k-mean clustering: I: designated ``hormone receptors positive/luminal-like’’ and II: designated ``hormone receptors negative’’, including both basal-like and Her-2/neu+ tumors. The most important factors for dataset variance were ER status, followed by PgR, CK17, and CK5/6 statuses. Overall basal CKs were expressed in a fraction of cases comparable to that reported for East and West African case series. Lack of associations with age and tumor size may represent a special feature of basal-like breast cancer in Sudan.

scholarly journals Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women

1970 ◽  
Vol 28 (3) ◽  
pp. 157-162 ◽  
Author(s):  
MG Mostafa ◽  
MT Larsen ◽  
RR Love
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Lymph Node ◽  
Progesterone Receptor ◽  
Axillary Lymph Node ◽  
Histological Grade ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Her 2 ◽  
Neu Oncogene

Two-thirds of all women who develop breast cancer each year live in Asia. In many countries, including Bangladesh, there are few data on the pathological characteristics of breast tumours. The objectives of this study were a) to describe the estrogen receptor (ER), progesterone receptor (PR), and the expression of Her-2/neu oncogene expression status in a large series of breast cancers occurring in Bangladeshi women and b) to correlate these findings with the patients' age at diagnosis, tumour histological grade, and presence of axillary lymph node metastatic disease.Method: One thousand forty two cases were evaluated in a referral practice. Tumour sections were stained immunohistochemically using Dako 1D5 (ER) and Dako 636 (PR) and semiquantitatively scored for ER and PR expression. Three hundred thirty five of these cases were also stained using Dako c-erb2 oncoprotein and scored for Her-2/neu over-expression.Results: Estrogen Receptor expression was positive in 69.0%, PR expression was positive in 72.3%, and Her-2/ neu was over-expressed (IHC score 3+) in 28.4% of the cases. Her-2/neu over-expression did not consistently correlate with ER and PR expression. ER and PR expression were inversely associated with tumour histological grade. Cases with axillary lymph node metastases had higher rates of ER and PR expression. No significant association was observed with patient’s age.Conclusion: Estrogen Receptor, PR, and Her-2/neu expression frequencies and prognostic factor associations in Bangladeshi women with breast cancer referred for tumour marker testing are very similar to those reported in Western countries. These findings have important implications for ensuring optimal testing capacity for all patients with these tumours, to allow for appropriate choices of treatment. DOI: 10.3329/jbcps.v28i3.6509J Bangladesh Coll Phys Surg 2010; 28: 157-162

Clinical significance of extranuclear expression of hormone receptors in breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 644-644
Author(s):  
R. Kim ◽  
M. Kaneko ◽  
K. Arihiro ◽  
M. Emi ◽  
K. Tanabe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Signaling Pathways ◽  
Clinical Significance ◽  
Cross Talk ◽  
Hormone Receptors ◽  
Growth Factor Signaling ◽  
Breast Cancers ◽  
Er Positive ◽  
Her 2 ◽  
Positive Breast Cancer

644 Background: Hormone receptor (HR)-positive breast cancer cells grow through estrogen receptor (ER)-signaling pathways that mediate both genomic and nongenomic actions, which cross-talk with growth factors associated with resistance to tamoxifen. The aim of this study is to explore the clinical significance of extranuclear expression of ER and PR in the cross-talk between HR and growth factor signaling pathways. Methods: We examined the extranuclear expression of ER and PR in 219 primary breast cancers by immunohistochemical staining. Specimens showing such expression were further examined for the expression of pAkt and aromatase. Due to heterogeneity, staining was scored on the basis of intensity and distribution in the tumors. Results: Extranuclear expression of ER or PR was observed in 21 cases (9.5%), which included 4 cases (19.0%) for ER and 20 cases (95.2%) for PR. Among these patients, HER-2, pAkt, and aromatase-positivity were observed in 14 cases (66.6%), 13 cases (61.9%), and 14 cases (66.6%), respectively. On the basis of nuclear HR expression, 11 of these cases were categorized as ER-positive/PR-negative, while 2 were ER-negative/PR-positive. Of those 13 cases, increased pAkt staining was found in 11 cases (84.6%). In particular, among the 11 ER-positive/PR-negative, elevated pAkt and aromatase were found in 10 (90.9%; p<0.01) and 9 cases (81.8%), respectively. Conclusion: PR is more frequently expressed extranuclearly than ER in primary breast cancer, and extranuclear HRs cross-talk with the Akt/HER-2-signaling pathway and activation of aromatase, providing an explanation for the observation that aromatase inhibitors are more beneficial than tamoxifen for ER-positive/PR-negative patients. No significant financial relationships to disclose.

Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 624-624 ◽  
Author(s):  
J. Wu ◽  
D. Mirchandani ◽  
J. A. Smith ◽  
G. Inghirami ◽  
D. Roses ◽  
...  
Keyword(s):  
Hormone Receptor ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
P53 Mutation ◽  
Breast Cancer Cell Lines ◽  
Breast Cancers ◽  
Term Survival ◽  
Exact Test ◽  
Her 2 ◽  
The Difference

624 Background: P27kip1 is a nuclear protein that controls the cell cycle by inhibiting cyclin dependent kinases. In breast cancer cell lines, both estrogen and her-2/neu degrade p27 through the ubiquitin-proteasome pathway. T1N0M0 breast cancers with high p27 expression have excellent long-term survival (Loda et al, Cancer Research 1998), now we examine the association of low p27 and other prognostic factors in these patients. Methods: 122 T1N0M0 infiltrating ductal carcinoma were examined using immunohistochemistry. Specific monoclonal antibodies were used against estrogen receptor (ER), progesterone receptor (PR), Her-2/neu, p53 and p27. Percentage of cells stained were considered negative (or low for p27) if: ER <10%, PR <10%, p53<40%, her-2/neu DAKO score ≤ 1+, p27 (nuclear stain) <50%. Results: In T1a/bN0M0 tumors, 4/5 (80%) of low p27 tumors were also hormone receptor negative, while only 5/63 (8%) of the high p27 tumors were hormone receptor negative (P< 0.001, Fisher’s exact test). Although T1cN0M0 tumors showed a similar trend [4/12 (33%) of low p27 vs. 7/42 (17%) of high p27 tumors were hormone receptor negative], the difference was not statistically significant. No correlation was seen between low p27, her-2/neu, or p53 mutation. Conclusion: There is an association of low p27 and loss of hormone receptors in T1a/bN0M0 breast cancers, which may identify a subset of patients with a worse prognosis. Exploring the causes of p27 dysregulation (e.g., ubiquitin ligase overexpression) may shed further light on the significance of these associations. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document